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Abstract  
In this report we describe the contribution of prostaglandin E-2 (PG)E2 derived from the 
inducible microsomal PGE-synthase type-1 (mPGES-1) to the epidermal growth factor receptor 
(EGFR) oncogenic drive in tumor epithelial cells and in tumor bearing mice. We investigated the 
mechanism controlling the mPGES-1 expression in HT-29, A431 and A549 tumor cells following 
EGFR stimulation, focusing on the transcriptional activity of Egr-1, a factor readily up-regulated by 
epidermal growth factor (EGF). The Egr-1 rise provoked the over-expression of mPGES-1 
messenger and protein, and enhanced PGE2 formation. These changes were suppressed either by 
silencing Egr-1, or by up-stream blockade of EGFR or ERK1/2 signals. Further, in a clonogenic 
assay on tumor cells, EGF induced a florid tumorigenic phenotype, which regressed when mPGES-
1 was silenced or knocked down. EGF-induced mPGES-1 overexpression in epithelial cell reduced 
E-cadherin expression, while enhancing that of vimentin, suggesting an incipient mesenchimal 
phenotype. Additionally, inhibiting the EGFR in mice bearing the A431 tumor, the mPGES-1 
expression and the tumor growth, exhibited a parallel decline. In conclusion, these findings provide 
novel evidence that a tight cooperation between the EGF/EGFR and mPGES-1 leads to a significant 
tumorigenic gain in epithelial cells, and provide clues for controlling the vicious association. 
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Introduction 
Prostaglandins, mainly prostaglandin E-2 (PG)E2, have assumed an important role in cancer 
biology because evidence demonstrates their involvement in cancer development as they exert a 
tumorigenic action. The clearest evidence has been the observation that overexpression of the 
inducible cyclooxygenase-2 (COX-2), and as a consequence, increased PGE2 synthesis, was 
causally associated with the growth and aggressiveness of human colon cancer (Eberhart et al., 
1994; Wiesner et al., 2001). These observations were later extended to many other solid tumors 
(Menter et al., 2010). 
Although PGE2 is a well know mediator of inflammation, it is evident that PGE2 exerts 
pleiotropic effects in tumors, promoting proliferation, survival, angiogenesis, migration and 
invasion. This multitude of PGE2 effects has been attributed to pro-survival and proliferative signals 
including: PI3K/Akt (Tessner et al., 2004), MAPK-ERK1/2 (Pozzi et al., 2004), cyclic adenosine 
monophosphate (cAMP)/protein kinase A (PKA) (Leone et al., 2007), epidermal growth factor 
receptor (EGFR) ( Pai et al., 2002; Buchanan et al., 2003; Donnini et al., 2007) and activation of β-
catenin/TCF in colorectal cancer cells (Castellone et al., 2005).  
Recent investigations have focused on PGE2 synthases (mPGES-1, mPGES-2 and cPGES), 
specifically on mPGES-1, the only inducible enzyme among those so far identified in cells. 
Whereas cPGEs and mPGEs-2 are constitutively expressed at relatively low levels, mPGES-1 is 
highly inducible (Samuelsson et al., 2007). All enzymes, being downstream of COX-2, act 
selectively on PGE2 synthesis, thus circumventing the issue of blocking the formation of protective 
prostaglandins associated with COX-2 inhibitors.  
mPGES-1 upregulation has been detected in many epithelial tumors (Yoshimatsu et al., 
2001a; Yoshimatsu et al., 2001b; Golijanin et al., 2004¸Choe et al., 2005), and its silencing has 
been reported to reduce pre-neoplastic lesions (Nakanishi et al., 2008). mPGES-1 tumorigenic 
potential has also been demonstrated in cell cultures, exemplified by HEK293 cells, in which co-
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transfection of COX-2 and mPGES-1 induced an increase in proliferation in vitro, and in vivo, 
when these engineered cells were inoculated in nude mice, formed large and vascularized tumors 
(Kamei et al., 2003; Kamei et al., 2009). Despite the evidence linking mPGES-1 and tumorigenesis, 
most studies investigating the inducible nature of the enzyme in cultured cells have been performed 
using a variety of inflammatory stimuli (LPS, IL-β, TNFα and others) (Naraba et al., 2002; 
Subbaramaiah et al., 2004; Cheng et al., 2004), while little is known about the behavior of the 
enzyme in tumor cells challenged with oncogenic stimuli. 
Here, we investigated mPGES-1 regulation in cultured epithelial tumor cells exposed to 
epidermal growth factor (EGF), an oncoprotein which, through its receptor EGFR, is responsible for 
tumorigenesis in a wide array of solid tumors (Ciardiello and Tortora, 2008). We used three cell 
lines, representative of colon (HT-29), epidermoid (A431), and lung (A549) tumors, examining the 
mPGES-1 expression following EGFR activation by EGF. We also studied in detail the expression 
of transcription factors (e.g. Egr-1, NFkB) relevant to the enzyme, as well as the signalling pathway 
downstream of EGFR activation (ERK1/2). The tumorigenic profile of epithelial cells was analyzed 
by the clonogenic assay, and by evaluating the potential development of a mesenchimal transition 
phenotype through the assessment of e-cadherin and vimentin expression in either wild type or 
mPGES-1 knockdown tumor cells. We also investigated the effect of inhibiting the EGFR in tumor 
bearing mice on mPGES-1 expression and tumor growth, finding a parallel decline of both. The 
results of this study provide further evidences for the pro-tumorigenic role of PGE2 in epithelial 
cells of diverse lineage as we demonstrate the existence of a tight link between the EGF/EGFR, 
Egr-1, and mPGES-1 molecular pathway and tumor progression. 
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Results 
EGFR activation up-regulates mPGES-1 expression 
The EGFR ligand, EGF (25 ng/ml) up-regulated mPGES-1 expression both at protein (18 h, 
Fig. 1A and B) and messenger level (6 h, Fig. 1C) in all cell lines, colon HT-29, epidermoid A431, 
and lung A549 carcinoma cells. The enzyme up-regulation was accompanied by increased PGE2 
secretion, ranging from 2.3 to 2.7-fold over control, depending on the cell line (Fig. 1D). On the 
contrary, neither mPGES-2 nor cPGES expression were significantly modified by EGF treatment 
(Fig. 1A). EGF also induced COX-2 expression, although in a manner which was variable in time 
and extent, depending of the cell line (Fig. 1A, see legend). 
To further explore the EGFR-induced up-regulation of mPGES-1, we studied mPGES-1 
promoter-driven transcription in the above cell lines, after transfection with plasmids bearing 
fragments of the mPGES-1 promoter differing in nucleotide length (from-1100 to +30). EGF 
consistently augmented mPGES-1 transcription, expressed either as fold induction relative to the 
empty plasmid, or absolute values of relative luciferase units (RLU) (Fig. 2A and table 1, 
respectively). The variable extent of mPGES-1 induction observed in the cell lines used was 
dependent on cell phenotype and on the length of the mPGES-1 promoter (table 1). The shorter 
plasmid (from -154 to +30), containing GC-rich elements, was sufficient to drive the mPGES-1 
transcription (Fig. 2A). This suggest that Egr-1, an inducible zinc finger protein that recognizes the 
GC-rich consensus DNA sequence, is involved in EGF-mediated mPGES-1 expression.  
 
mPGES-1 up-regulation requires ERK1/2 and Egr-1 activation downstream to EGFR 
We studied the expression of Egr-1 in tumor cells exposed to EGF. Because EGF /EGFR 
signalling is known to promote solid tumor growth via activation of the MAPK/ERK1/2 pathway 
(Dasari and Messersmith, 2010) we evaluated ERK1/2 involvement in the expression of mPGES-1. 
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Indeed, EGF (25 ng/ml) induced Egr-1 expression and ERK1/2 phosphorylation in the three cell 
lines analysed in a time-dependent manner, both events peaking between 15 and 45 min (Fig. 2B). 
Next, we studied  the EGF-induced  activation of Egr-1 analyzing both its translocation from 
the cytosol to the nucleus (Western blot and immunohistochemistry), and the induction of its 
transcriptional activity. Egr-1 translocation was evidenced by the time-related enrichment of protein 
or fluorescence into the nucleus of HT-29 cells (Fig. 2C and D). Similarly, we observed an increase, 
in all cell lines, of luciferase activity of Egr-1-Pro36LUC, a construct containing two Egr-1 binding 
sites inserted upstream of a prolactin minimal promoter (24) (Fig. 2E), demonstrating that EGF 
induces both Egr-1 expression and activity. 
A number of experiments firmly established the involvement of EGFR-MAPK pathway in 
Egr-1 and mPGES-1 expression. Thus, blockers of either EGFR or ERK1/2 (AG1478, and U0126, 
respectively) suppressed the EGF-induced up-regulation of both Egr-1 and mPGES-1 in all cell 
lines examined (Fig. 2F). 
The involvement of Egr-1 in the inducing mPGES-1 in tumor cells, was further documented 
by experiments in which Egr-1 expression was knocked down. In fact, silencing Egr-1 in epithelial 
tumor cells, abolished its overexpression provoked by EGF (Fig 3A), concomitantly reducing the 
mPGES-1 induction (Fig 3A). Conversely, in experiments in which tumor cells were transfected 
with the Egr-1 expression plasmid pLNCX-NGFI-A (Clone Egr-1+/+) we found that higher levels of 
Egr-1 expression (clone Egr-1+/+) corresponded to higher mPGES-1 protein levels (Fig. 3B, 
p<0.001). Further, in tumor cells silenced for Egr-1, EGF failed to induce mPGES-1 transcription 
(Fig. 3C). Additional evidence for the Egr-1 role was obtained by performing the ChIP assay in HT-
29 cells treated with EGF for 45 min. In these conditions Egr-1 was found to be specifically bound 
to the mPGES-1 promoter only in cells stimulated by the growth factor, whereas its binding to 
control cells was negligible (Fig 3D). Thus, EGF appears to promote the recruitment of Egr-1 
toward the mPGES-1 promoter. 
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All together these data demonstrate the requirement for ERK1/2/Egr-1 pathways 
downstream of EGFR for induction of mPGES-1 expression. 
We also explored whether the mPGES-1 gene was regulated by NFkB, a transcription factor 
known to convey inflammatory and oncogenic stimuli to a wide variety of genes (Lin and Karin, 
2007). Pre-treatment of HT-29 cells with IKK, an inhibitor of NFkB that leads to inhibition of 
NFkB activity, suppressed the EGF-induced mPGES-1 expression, suggesting the involvement of 
this transcription factor in EGF-dependent induction of mPGES-1 gene in tumor cells (data not 
shown).  
 
Silencing mPGES-1 expression reduces epithelial cell tumorigenicity  
The role of mPGES-1 expression on the cell tumorigenic potential following EGFR 
activation was assessed by the clonogenic assay. While EGF induced colony formation in both HT-
29 and in A549 cells, mPGES-1 gene knockdown in either cell types, reduced by 3 to 5 fold the 
EGFR response (Fig. 4A).  
This suggests that mPGES-1/ PGE2 signaling is implicated in the malignancy induced by 
EGF. Because the regulation of E-cadherin and vimentin are well established biomarkers of 
enhanced malignancy, signaling the initiation of epithelial-mesenchymal transition (EMT) process 
(Thiery et al., 2009), we investigated their expression in A549 cell types. Indeed, in A549 cells wild 
type, or transfected with non target shRNA, EGF decreased E-cadherin, while increasing vimentin 
expression (Fig. 4B). Conversely, in A549 knocked down for mPGES-1, EGF failed to regulate 
both proteins-mediated adhesion/movement. Thus mPGES-1 appears to control the EGF/EGFR 
oncogenic drive by governing the development of the EMT program (Fig. 4B).  
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Tumor growth decline, caused by EGFR blockade, is associated to the downregulaton of 
mPGES-1 expression 
The functional association between EGFR and mPGES-1 signaling was further investigated 
in mice bearing human A431 xenograft, which expresses high EGFR levels (Johns et al., 2002). 
A431 cells (107 cells) were inoculated in nude mice. Treatment with vehicle control (0.5% 
methylcellulose) or the EGFR inhibitor AG1478, (400 µg/mice, 10 days) started 4 days after cells 
implantation, a time at which tumors were measurable (3 mm diameter). Tumor size in controls 
increased steadily, reaching an average volume of 400 mm3, 7-fold higher at day 10, relative to day 
4. AG1478 administration reduced tumor growth by 50% starting from day 8 (P < 0.01), relative to 
the vehicle- group (Fig. 5A). During the course of treatment neither body weight loss nor signs of 
toxicity were observed. In AG1478 treated tumors, mPGES-1 expression, analyzed by Western blot 
and immunohistochemistry, was significantly reduced relative to control specimens (Fig. 5B and C, 
p<0.05). Consistently, mPGES-1 expression in tumor samples correlated with tumor volume (Fig. 
5B). Indeed, treatment of human A431 xenograft with selective inhibitors of mPGES-1 activity, 
was found to reduce both growth and receptor phosphorylation of tumors (manuscript in 
preparation).  
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Discussion 
The keen interest in prostaglandin biosynthesis stems from the recognition that PGE2 exerts 
an important role in the initiation and progression of several epithelial tumors (Menter et al., 2010). 
In this study we focused on microsomal prostaglandin synthase (mPGES-1) examining its inducible 
behavior in cultured epithelial tumor cells (HT-29, colon, A431, squamous cell, and A549, lung 
adenocarcinoma) following stimulation by EGF. Although a number of reports have described the 
relationship between mPGES-1 overexpression and tumor growth, the evidence that the enhanced 
malignancy is linked to a transduction loop between the prostanoid and the EGF system, is 
fragmentary (Wang and Dubois, 2010, Hanaka et al., 2009; Nah et al., 2010; Lu et al., 2011). Our 
aim was to demonstrate that the mPGES-1/PGE2 and the EGF axis provides a cohesive program for 
malignancy in epithelium. Here, we show that EGFR stimulation induces mPGES-1 up-regulation 
and increases PGE2 production, through the specific activation of gene transcription pathway, 
i.e.Egr-1, in epithelial tumor cells of diverse lineage (see below). In addition, we show that 
epithelial cells expressing mPGES-1 evolve toward a distinct tumor phenotype, and produce a fast-
growing tumor mass when inoculated in nude mice. 
The EGF induced mPGES-1 over-expression, preceded by the rise of its encoding mRNA, 
was similar in the three cell lines examined. In the promoter region of the mPGES-1 gene, several 
binding sites for transcription factors have been identified, including GC boxes for Egr-1, NFkB, 
AP-1 and c/EBP response elements (Diaz-Munoz et al., 2010). The detailed analysis of the 
mPGES-1 promoter (from-1100 to +30), performed by transfecting tumor cells with mPGES-1 
promoter constructs of different length, revealed a consistent enhancement of the EGF-driven 
mPGES-1 transcription, enabling also to identify the minimal sequence, containing solely the Egr-1 
binding sequence, capable of eliciting a response. The ChIP assay corroborated these observations 
by showing the Egr-1 specific binding within the  mPGES-1 promoter. Thus, these findings 
delineate the role of Egr-1 in the EGFR-induced expression of the mPGES-1 gene in epithelial 
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tumor cells. The interplay between mPGES-1 and Egr-1 expression was clearly demonstrated by 
experiments involving either Egr-1 silencing through siRNA, or forcing its expression through 
transfection with the pLNCX-NGFI-A Egr-1 plasmid, resulting in abrogation of mPGES-1 
promoter activity and expression or mPGES-1 over-expression, respectively. Although, these data 
clearly point to Egr-1 as an important transcription factor of mPGES-1 gene expression following 
EGF/EGFR stimulation, one ought to consider the vast redundancy of signals present in neoplastic 
epithelial cells. Among the wide repertoire of pro-inflammatory stimuli known to induce mPGES-1 
gene (PMA, IL-1β, TNFα or LPS), recently some of us described the involvement of NFkB in both 
Egr-1 and mPGES-1 expression in macrophages exposed to LPS (Diaz-Munoz et al., 2010). Indeed, 
in HT-29 tumor cells, inhibition of NF-kB activity by the use of an IKK inhibitor prevented the 
EGF-induced mPGES-1 over-expression, suggesting that also in tumor cells the mPGES-1 
transcription could be controlled by several transcription factors, whose action might be exerted in 
cell and in a context-dependent manner (Naraba et al., 2002; Cheng et al., 2004; Diaz-Munoz et al., 
2010 ; Deckmann et al., 2010). Inhibition of NF-kB activity precludes from distinguishing from its 
transcriptional effect on mPGES-1 by direct binding of mPGES-1 promoter or indirectly, by 
altering Egr-1 expression (Diaz-Munoz et al., 2010).  
The connection between EGF/EGFR and mPGES-1 in promoting tumorigenicty in epithelial 
cells, so far largely surmised from work on non-tuor cells (e.i. synoviocytes) (Nah et al., 2010), is 
here clearly demonstrated by two lines of evidence. First, the clonogenic assay shows that 
abrogation of the mPGES-1 gene in tumor epithelial cells (HT-29), markedly reduces the EGF 
tumorigenic potential. Second, the in vivo demonstration that blockade of EGFR by AG1478 (a TK 
receptor inhibitor) in a xenograft model of epithelial tumor (A431) produces a decrease of tumor 
mPGES-1 expression while reducing tumor growth. To be noted that this tumor line features the 
highest inducible mPGES-1 and PGE2 levels among the cells examined (see Fig 1) and a very 
robust EGF/EGFR system (Thoren and Jakobsson, 2000). 
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The PGE2 leveraging effect on EGF tumorigenic action has been explained according to 
various mechanisms, among which, the transactivation of EGFR has been the most studied (Pai et 
al., 2002; Buchanan et al., 2003; Donnini et al., 2007). However, the reported mechanisms, 
involving the regulation of E-cadherin expression by PGE2, might contribute to enhance 
tumorigenesis in solid cancer (Mann et al., 2006 ; Dohadwala et al., 2006). For example, PGE2 has 
been shown to suppress E-cadherin expression, through the transcriptional repression of Snail and 
ZEB genes (Dohadwala et al., 2006). Furthermore, the EGF-induced Snail expression leads to PGE2 
increase in colon tumor cells by inhibiting PGDH, the main degrading enzyme for prostanoids in 
tumors (Mann et al., 2006). It is of interest that Egr-1 has been reported to induce Snail by binding 
to its promoter, thus acting as a trigger for the  epithelial mesenchymal  transition (Grotegut et al., 
2006). Indeed, the marked changes of E-cadherin and vimentin expression, noted here in A549 wild 
type but not in mPGES-1 knock down, provide evidence for the relevance of mPGES-1 in the 
incipient epithelial to mesenchymal transition, a process which confers enhanced tumorigenic 
properties to epithelial cells, in terms of invasion and ability to form metastasis. Additionally, the 
mPGES-1/PGE2 biosynthetic pathway might contribute to cancer progression through other 
cytokine/growth factors, as exemplified by the reported synergism between PGE2 and FGF-
2/FGFR1 system in sustaining tumor vascularity (Finetti et al., 2009).  
The number of mechanisms in which PGE2 and consequently mPGES-1, is involved in 
boosting the EGF-driven tumorigenicity in epithelial cells, signals its key role in rewiring cells 
toward a tumor phenotype. Conceivably, strategies aimed to interfere with mPGES-1 signaling 
might be a valuable addition to the armamentarium for controlling epithelial tumor progression. 
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Materials and methods  
Reagents 
Reagents were as follows: AG1478, IKK inhibitor VII and U0126 (Calbiochem, Darmstadt, 
Germany), anti-β-actin, anti-vimentin, (Sigma, Milan, Italy); anti-mPGES-1, anti-mPGES-2, anti-
cPGES and anti-COX-2 antobodies (Cayman Chemical, Vincibiochem, Florence, Italy); EGF 
(RELIAtech, Wolfenbuttel, Germany), anti phospho-p44/42 MAPK, anti-EGFR (Cell Signalling, 
Pero, Italy); anti Egr-1 (Santa Cruz, Heidelberg, Germany); anti-E Cadherin antibodies (DAKO, 
Milan, Italy). Where not indicated, reagents were from Sigma. 
 
Cell Lines  
HT-29, human colorectal adenocarcinoma cells, A431 human epidermoid carcinoma and A549 
human lung carcinoma cells were obtained from ATCC and cultured as recommended. A549 wild 
type (WT), mPGES-1 knockdown (Kd) and non-target shRNA cells obtained and cultured as 
described (Hanaka et al., 2009). 
 
Western blotting 
4 x 105 cells were plated in 60 mm dishes, serum deprived (0.1% FCS, 24 h), then exposed to EGF 
in the presence or absence of MAPK, EGFR or NFκB inhibitors. To assess the translocation of Egr-
1 from cytosol to nucleus, after treatment with EGF for the indicated times, cells were 
scraped/trypsinized, and homogenized on ice in a lysis buffer, containing 0.1 mM EGTA, 0.1 mM 
EDTA,10 mM Hepes, 10 mM KCl, protease and phosphatase inhibitors. After incubation on ice for 
15 min, Nonidet-P-40 was added to cell lysates which were centrifuged (10.000 rpm, 30 sec). The 
supernatant contains the cytosolic fraction while the pellet was solubilized in lysis buffer containing 
1 mM EGTA, 1 mM EDTA, 20 mM Hepes, 10 mM NaCl, 1%protease and phosphatase inhibitors, 
followed by incubation on ice for 10 min and centrifugation (14.000 rpm, 5 min). The supernatant 
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contains the nuclear fraction. An equal amount of proteins were loaded on SDS PAGE gel and then 
transferred to a nitrocellulose membrane. Western blotting was performed as described (Donnini et 
al., 2007). Images were digitalized with CHEMI DOC Quantity One programme, blots were 
analysed in triplicate by densitometry using NIH Image 1.60B5 software, and the arbitrary 
densitometric units (ADU) were normalized to ADU for β-actin. 
 
PGE2 immuno-assays 
PGE2 was measured by an EIA kit (Prostaglandin E2 EIA kit-Monoclonal, Cayman Chemical). 
Cells were exposed to EGF (25 ng/ml, 24 h) and treated with 10 µM arachidonic acid. Cell culture 
supernatants were assayed directly at a final dilution of 1:10 to 1:500. PGE2 concentration was 
expressed as [pg/ml], normalized to total protein concentration. 
 
Real-Time PCR 
Total RNA was obtained using RNA mini kit (Qiagen, Inc., Milan, Italy). RNA (0.5 µg) was 
reverse transcribed using a RT-PCR kit (Applied Biosystems, Foster City, USA). mPGES-1 mRNA 
detection was measured using the optimized TaqMan assay-on-demand (Applied Biosystems) and 
the expression of the mRNAs in each sample was calculated by referring to an external reference 
curve generated with universal human reference RNA (Stratagene, La Jolla, USA). The results were 
expressed as fold increase. 
 
Luciferase activity 
Cells were transiently transfected with luciferase constructs containing different deletions of the 
murine promoter of mPGES-1 cloned in the pxP2-LUC plasmid: mPGES-1-1100 (-1100 to +30) 
mPGES-1-895 (-895 to +30), mPGES-1-483 (-483 to +30) and mPGES-1-154 (-154 to + 30), or 
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with a construct containing two Egr-1 consensus binding sites insert upstream of a prolactin 
minimal promoter (Egr-1-Pro36LUC) (Diaz-Munoz et al., 2010; Crosby et al., 1991). 
Transfections were performed using Effectene Transfection Reagents (Qiagen, Milan, Italy) 
according to manufacturer’s instructions. Transfection efficiency was assessed by co-transfection 
with a plasmid harbouring the Renilla luciferase gene under control of a constitutive promoter 
(Promega, Madison, USA). 24 h following transfection, cells were starved for 24 h and stimulated 
for 18 h (mPGES-1 LUC) or 45 min (Egr-1-Pro36LUC) with EGF (25 ng/ml) and then lysed. 
Luciferase reported assays were performed using Steady Glo and dual luciferase reporter assay 
reagents (Promega), and activity was measured using a Tecan Infinite 200Pro Luciferase activity 
was normalized according to the protein expression for each condition. 
 
Transfection 
For siRNA transfection: the siRNAs sequences (human mPGES-1: 5’-
CGGGCTAAGAATGCAGACTTT-3’, Egr-1: 5’-CCCGTCGGTGGCCACCACGTA-3’) were 
from Qiagen. The day before transfection, cells were trypsinized and 3 x 105 cells were seeded in 6-
well plates. Transient transfection of siRNA was carried out using HT-29 transfection reagent 
(Altogen, Las Vegas, Nevada, USA) according to the manufacturer instructions. Cells were assayed 
48 h after transfection. 
For DNA transfection: transient transfection of Egr-1 expression plasmid pLNCX-NGFI-A (Clone 
Egr-1+/+) generously provided by Dr. A. M. Pérez-Castillo (Instituto de Investigaciones 
Biomédicas,Madrid, Spain) (Pignatelli et al., 1999), was carried out using Effectene transfection 
reagent (Qiagen, Italy) according to the manufactures instructions. Cells were assayed 48 h after 
transfection. 
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Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation assay (ChIP) assays were performed as described (Díaz-Muñoz et 
al. 2010). HT-29 cells (6×106) were maintained in RPMI with 0.5% FCS for 24 h prior stimulation 
with EGF for 45 min. Cells were then fixed with 1% formaldehyde for 5 min at 37 °C and lysed in 
ice-cold lysis buffer (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.1% NP-40 and 
protease inhibitors) for 10 min at 4 °C. Nuclei pellet was suspended in nuclear lysis buffer (50 mM 
Tris–HCl pH 8, 10 mM EDTA, 1% SDS and protease inhibitors) and incubated on ice for 10 min. 
DNA was shared by sonication and lysates were cleared by centrifugation and diluted in ChIP 
dilution buffer (50 mM Tris–HCl pH 8, EDTA 5 mM, NaCl 200 mM, and 0.5% NonidetP-40). 
Lysates were precleared with salmon sperm/protein A-agarose. A sample of “input DNA” (positive 
control (+)) was collected at this point. Protein–DNA complexes were immunoprecipitated 
overnight at 4 °C with 2 µg of the anti-Egr-1 or non-immune rabbit serum as a control (negative 
control (-)). Antibody–protein–DNA complexes were then captured using salmon sperm 
DNA/protein A agarose for 30 min followed by washes with wash buffer (20 mM Tris–HCl pH 8, 2 
mM EDTA, 0.1% SDS, 1% NP-40, and 500 mM NaCl) and TE buffer (20 mM Tris–HCl, and 2 
mM EDTA). The protein/DNA complexes were eluted using extraction buffer (20 mM Tris–HCl, 2 
mM EDTA, and 2% SDS) and disrupted by heating at 65 °C overnight followed by proteinase K 
treatment for 2 h at 45 °C. DNA was extracted with a DNA Purification system (Promega). PCR 
was conducted using promoter specific primers (Applied Biosystem,): mPGES-1, sense 5′-TCC 
GGC AAC TGC TTG TCT TTC TCT-3′ and antisense 5′- TGT GAT CAG CTC GAC AGA GGA 
GCA-3′. PCR products obtained after 35 cycles were separated on 2% agarose gels. 
 
Immunofluorescence analysis 
HT-29 cells (3x104 cells/well on glass cover-slips placed into 24 multiwell plates) were serum 
starved and treated with EGF for 45 min. Cells were fixed in paraformaldehide for 5 min and then 
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washed in PBS with Ca
2+ 
and Mg
2+
. Cells were then permeabilized in 0.25% Tween-20 in PBS for 
10 min. After the blocking of unspecific bindings in 3% bovine serum albumin (BSA) for 30 min 
the cells were incubated overnight at 4°C with a polyclonal antibody against Egr-1 (Santa Cruz) 
diluted 1:40 in PBS/0.5% BSA. Samples were then incubated with secondary antibody TRITC 
conjugated (Sigma) and assessed by fluorescence microscope (Eclipse TE300, Nikon) at 40X 
magnification and images taken by a digital camera. 
 
Clonogenic assay  
For clonogenic assay, HT-29 cells, after silencing for mPGES-1, and A549 cells, WT, non-target 
shRNA, or Kd were incubated with EGF (25 ng/ml) for 18 h. Following EGF treatment, cells were 
plated in 60 mm culture dishes (HT-29 at a density of 2000 cells/dish, A549, 150 cells per dish) in 
medium containing 10% FCS, and then kept in a humidified incubator at 37°C and 5% CO
2 for 3 or 
2 weeks, respectively. Colonies (>75cells) with 50% plate efficiency were fixed and stained with 
0.05% crystal violet (Sigma, Italy) in 10% ethanol and counted. 
 
In vivo tumor xenograft  
Experiments have been performed in accordance with the EC guidelines and National Ethical 
Committee. Immunodeficient mice (5 week-old female athymic nude mice, Harlan, USA) were s.c. 
inoculated in the right flank with 107 A431 cells in 50 µl/PBS. After 4 days, when tumors reached a 
70-100 mm3 volume, animals were randomly assigned to 2 different experimental protocols. At this 
time i.p. AG1478 treatment (400µg/mouse, daily, 8 mice), or vehicle (0.05% methylcellulose, 8 
mice) started. Mice were treated with 200 µl volume i.p., for 10 consecutive days. Data are reported 
as tumor volume (mm3). Animals were observed daily for signs of cytotoxicity, at day 10 were 
sacrificed by CO2 asphyxiation, and tumors collected and split in two parts. One part was 
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immediately frozen in liquid nitrogen for Western blotting as described (1), the other part was 
embedded in Tissue-Tek O.C.T. (Sakura, San Marcos, USA), for histology. Seven thick cryostat 
sections from tissue samples were stained with hematoxylin and eosin, and adjacent sections were 
used for immunohistochemical staining with the anti-mPGES-1 (Cayman). Cryostat sections were 
first fixed in acetone 20°C and incubated for 10 min in 3% H2O2, washed in TBS, then incubated 
in a blocking reagent (KIT Immunoperoxidase Secondary Detection System, Chemicon). Anti-m-
PGES-1 diluted 1:100 (5 µg/ml) in TBS and 0.05% BSA was applied for 1 h at room temperature. 
Sections were then washed (TBS) and incubated for 10 min in the appropriate species-specific 
biotinylated secondary antibodies (goat anti-rabbit IgG, KIT Immunoperoxidase Secondary 
Detection System, Chemicon). After washing, the sections were incubated for 10 min in 
streptavidin-conjugated HRP and exposed to 3,3-diaminobenzidine tetrahydrocloride for 8 min to 
produce a brown reaction product. Sections were then counterstained in hematoxylin and mounted 
in Aquatex (Merck, Rahway, NJ, USA). Western blotting analysis for mPGES-1 was performed as 
reported above (see Western blotting analysis). 
 
Statistical analysis 
Results are expressed as means ± SEM. Statistical analysis was performed using Student’s t test, 
analysis of variance (ANOVA) or Student-Newman-Keuls test for multiple comparisons. P<0.05 
was considered statistically significant. 
18	  
	  
Acknowledgments: We thank Dr. M. D. Díaz-Muñoz for the construction of mPGES-1 plasmids. 
This work has received financial support from the Associazione Italiana della Ricerca sul Cancro 
(AIRC) IG10731 (M.Z.), Istituto Toscano Tumori (ITT) (S.D.), Comunidad de Madrid S-
SAL2006/0015, Ministerio de Ciencia e Innovación SAF2010-18733 (M.F.), Ministerio de Ciencia 
e Innovación BFU2010-21055 (M.A.I.). 
 
Conflict of interest: The authors declare no conflict of interest. 
19	  
	  
References  
Buchanan FG, Wang D, Bargiacchi F, DuBois RN. (2003). Prostaglandin E2 regulates cell 
migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 
278(37):35451-7. 
Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. (2005). Prostaglandin E2 
promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 
310(5753):1504-10. 
Cheng S, Afif H, Martel-Pelletier J, Pelletier JP, Li X, Farrajota K et al. (2004). Activation of 
peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-
associated prostaglandin E2 synthase-1 expression in human synovial fibroblasts by interfering with 
Egr-1. J Biol Chem 279(21):22057-65. 
Choe MS, Zhang X, Shin HJ, Shin DM, Chen ZG. (2005). Interaction between epidermal growth 
factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the 
chemoprevention of head and neck cancer. Mol Cancer Ther 4(9):1448-55. 
Ciardiello F, Tortora G. (2008). EGFR antagonists in cancer treatment. N Engl J Med 
358(11):1160-74. 
Crosby SD, Puetz JJ, Simburger KS, Fahrner TJ, Milbrandt J. (1991). The early response gene 
NGFI-C encodes a zinc finger transcriptional activator and is a member of the GCGGGGGCG 
(GSG) element-binding protein family. Mol Cell Biol 11(8):3835-41. 
Dasari A, Messersmith WA. (2010). New strategies in colorectal cancer: biomarkers of response to 
epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in 
phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 
16(15):3811-8.  
20	  
	  
Deckmann K, Rörsch F, Steri R, Schubert-Zsilavecz M, Geisslinger G, Grösch S. (2010). 
Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB. Biochem 
Pharmacol 80(9):1365-72.  
Díaz-Muñoz MD, Osma-García IC, Cacheiro-Llaguno C, Fresno M, Iñiguez MA. (2010). 
Coordinated up-regulation of cyclooxygenase-2 and microsomal prostaglandin E synthase 1 
transcription by nuclear factor kappa B and early growth response-1 in macrophages. Cell Signal 
22(10):1427-36. 
Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M et al. (2006) Cyclooxygenase-2-
dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and 
snail in non-small cell lung cancer. Cancer Res 66(10):5338-45. 
Donnini S, Finetti F, Solito R, Terzuoli E, Sacchetti A, Morbidelli L et al. (2007). EP2 prostanoid 
receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor 
transactivation and iNOS and ERK1/2 pathways. FASEB J 21(10):2418-30. 
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. (1994). Up-
regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and 
adenocarcinomas. Gastroenterology 107(4):1183-8. 
Finetti F, Donnini S, Giachetti A, Morbidelli L, Ziche M. (2009). Prostaglandin E(2) primes the 
angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway. Circ Res 
105(7):657-66. 
Golijanin D, Tan JY, Kazior A, Cohen EG, Russo P, Dalbagni G et al. (2004). Cyclooxygenase-2 
and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the 
penis. Clin Cancer Res 10(3):1024-31. 
Grotegut S, von Schweinitz D, Christofori G, Lehembre F. (2006). Hepatocyte growth factor 
induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 25(15):3534-
45. 
21	  
	  
Hanaka H, Pawelzik SC, Johnsen JI, Rakonjac M, Terawaki K, Rasmuson A et al. (2009). 
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung 
cancer cells. Proc Natl Acad Science 106: 18757–62. 
Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK et al. (2002). Novel 
monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also 
recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer 
98(3):398-408. 
Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I. (2003). Potential role of 
microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 278(21):19396-405. 
Kamei D, Murakami M, Sasaki Y, Nakatani Y, Majima M, Ishikawa Y et al. (2009). Microsomal 
prostaglandin E synthase-1 in both cancer cells and hosts contributes to tumor growth, invasion and 
metastasis. Biochem J 425(2):361-71. 
Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, Di Prisco AM et al. (2007). PGE2 
inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and 
cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol 293(4):G673-G681. 
Lin WW, Karin M. (2007). A cytokine-mediated link between innate immunity, inflammation, and 
cancer, J Clin Invest 117:1175–83. 
Lu D, Han C, Wu T. (2011). Microsomal prostaglandin E synthase-1 promotes 
hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene 11 
doi: 10.1038/onc.2011.287. 
Mann JR, Backlund MG, Buchanan FG, Daikoku T, Holla VR, Rosenberg DW et al. (2006). 
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases 
prostaglandin E2 and promotes cancer progression. Cancer Res 66(13):6649-56. 
Menter DG, Schilsky RL, DuBois RN. (2010). Cyclooxygenase-2 and cancer treatment: 
understanding the risk should be worth the reward. Clin Cancer Res 16(5):1384-90.  
22	  
	  
Nah SS, Won HJ, Ha E, Kang I, Cho HY, Hur SJ, et al. (2010). Epidermal growth factor increases 
prostaglandin E2 production via ERK1/2 MAPK and NF-kappaB pathway in fibroblast like 
synoviocytes from patients with rheumatoid arthritis. Rheumatol Int 30(4):443-9. 
Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP et al. (2008). Genetic 
deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res 68(9):3251-9. 
Naraba H, Yokoyama C, Tago N, Murakami M, Kudo I, Fueki M et al. (2002). Transcriptional 
regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the 
transcription factor Egr-1. J Biol Chem 277(32):28601-8. 
Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. (2002). Prostaglandin E2 
transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and 
gastrointestinal hypertrophy. Nat Med 8(3):289-93. 
Pignatelli M, Cortes-Canteli M, Santos A, Perez-Castillo A. (1999). Involvement of the NGFI-A 
gene in the differentiation of neuroblastoma cells. FEBS Lett 461(1-2):37-42. 
Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, Breyer RM et al. (2004). Colon carcinoma cell 
growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 
279(28):29797-804. 
Samuelsson B, Morgenstern R, Jakobsson PJ. (2007). Membrane prostaglandin E synthase-1: a 
novel therapeutic target. Pharmacol Rev 59(3):207-24. 
Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D et al. (2004). 
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence 
for involvement of the transcription factor Egr-1. J Biol Chem 279(13):12647-58. 
Tessner TG, Muhale F, Riehl TE, Anant S, Stenson WF. (2004). Prostaglandin E2 reduces 
radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax 
translocation. J Clin Invest 114(11):1676-85. 
23	  
	  
Thiery JP, Acloque H, Huang RY, Nieto MA. (2009). Epithelial-mesenchymal transitions in 
development and disease. Cell 139(5):871-90.  
Thoren S, Jakobsson PJ (2000). Coordinate up- and down-regulation of glutathione-dependent 
prostaglandin E synthase and cyclooxygenase-2 in A549 cells inhibition by NS-398 and leukotriene 
C4. Eur J Biochem 267: 6428-6434. 
Wang D, Dubois RN. (2010). Eicosanoids and cancer. Nat Rev Cancer 10(3):181-93.  
Wiesner GL, Platzer P, Buxbaum S, Lewis S, MacMillen M, Olechnowicz J et al. (2001). Testing 
for colon neoplasia susceptibility variants at the human COX2 locus. J Natl Cancer Inst 93:635-9. 
Yoshimatsu K, Altorki NK, Golijanin D, Zhang F, Jakobsson PJ, Dannenberg AJ et al. (2001). 
Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin Cancer Res 
7(9):2669-74. (b) 
Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA et al. (2001). 
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. 
Clin Cancer Res 7(12):3971-6. (a) 
24	  
	  
Figure legends  
Figure 1. EGF promotes mPGES-1 expression and activity. (A) Analysis of mPGES-1, mPGEs-2, 
cPGEs and COX-2 in three cancer cell lines (HT-29, A431 and A549) in response to EGF (25 
ng/ml, 18 h for mPGES-1, mPGES-2 and cPGES, and 4 h for COX-2 in HT-29 and A431, and 8 h 
in A549). (B) Quantification of mPGES-1 expression in HT-29, A431 and A549. Data are reported 
as Arbitrary Density Unit (ADU) and represents the ratio between mPGES-1/Actin expression of 
three independent blots (***P<0.01). (B) Quantitative PCR for mPGES-1 mRNA expression in 
cells exposed to EGF (25 ng/ml) or fresh medium (Control, 6 h). mPGES-1 mRNA expression 
reported as fold increase compared to basal levels (n=3). (***P<0.001; **P<0.05). (C) EIA 
immunoassay for PGE2 production, expressed as [pg/ml] (n=3), in cells treated with EGF (black 
bar, 25 ng/ml) or fresh medium (white bar, Control) in presence of arachidonic acid (10 µM, 24 h) 
(***P<0.001).  
Figure 2. EGF promotes mPGES-1 transcriptional activity. (A) mPGES-1 transcription activity 
monitored through a luciferase assay with different mPGES-1 promoter constructs (described in 
material and methods) in cells exposed to EGF (25 ng/ml) or fresh medium. Data are shown as fold 
increase (EGF mediated RLU/basal RLU in absence of any stimulus). Results are representative of 
at least three independent assays. (B) ERK1/2 activity and Egr-1 expression in tumor cells exposed 
to EGF (25 ng/ml). Gel representative of three with similar results. (C) Western blotting analysis of 
Egr-1 expression in cytosol and nucleus in HT-29 exposed to EGF (25 ng/ml) for the indicated 
times. (D) Immunofluorescence analysis of Egr-1 expression (red) in HT-29 exposed for 45 min to 
EGF (25 ng/ml). Cell nuclei are revealed by DAPI staining (blue). White arrows in panels “EGF 
45” indicate the increased fluorescence in nucleus. Scale bars indicate 100 µm. Images taken at 
60X. (E) Transcriptional activity of Egr-1 monitored through a luciferase construct in cells exposed 
to EGF (25 ng/ml) or fresh medium (45 min), *P<0.01. (F) ERK1/2 activity (15 min), Egr-1 (45 
min) and mPGES-1 expression (18 h) in HT-29 exposed to EGF (25 ng/ml) in HT-29 cells 
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pretreated (30 min) with or without AG1478 (10 µM), or U0126 (10 µM). Gel representative of 
three with similar results.  
Figure 3. EGF-induced mPGES-1 expression is mediated by ERK-1/2 activity and Egr-1. (A) 
Western blot analysis of mPGES-1 in HT-29 transiently transfected with non targeting siRNA 
(siCont) or siRNA for Egr-1 (siEgr-1), and then exposed to EGF (25 ng/ml) or fresh medium for 18 
h. (B) HT-29, A431 and A549 cells were transiently transfected with the Egr-1 expression plasmid 
pLNCX-NGFI-A (Clone Egr-1+/+) and analyzed by western blot for expression of Egr-1 and 
mPGES-1 versus Actin. Gel representative of at least three with similar results. (C) mPGES-1 
transcription activity in A549 cells silenced for Egr-1 (si-Egr-1) or with a random nucleotide (si-
Cont) and then exposed to EGF (25 ng/ml) or fresh medium . Data are expressed as luciferase 
activity in RLUs±SD. Results are representative of at least three independent assays. (D) Analysis 
of the specific binding of Egr-1 to mPGES-1 promoter region in Ht-29 cells by ChIP assays. Egr-1 
transcription factor was immunoprecipitated from cells stimulated with EGF (25 ng/ml) for 45 min. 
Immunoprecipitated DNA was amplified with specifics primers for the mPGES-1 proximal 
promoter region. As a positive control, PCR was performed on chromatin fragments isolated before 
immunoprecipitation (+). Immunoprecipitation with a normal rabbit serum was carried out in 
parallel as negative control (-).Shown is a representative experiment of the three experiment 
performed. 
Figure 4. Knockdown of mPGES-1 reduces clonogenicity of tumor cells. (A) Colony formation 
capability of HT-29 cells,  (si-Cont, and si-mPGES-1 clones), and A549 cells, (non-target shRNA, 
and mPGES-1 knockdown clones) in response to EGF . Colonies (>75 cells) with 50% efficiency 
were counted. Results are expressed as the increase (Δ) number of colonies in  HT-29 cells and 
A549 in response to EGF over control (*P<0.01). The absolute number of colonies ± SD of three 
experiments was: HT-29, si-Cont, Ctr: 15 ± 2, EGF: 70 ± 10; si-mPGES-1, Ctr: 20 ± 7; EGF: 28 ± 
6; A549, non-target shRNA, Ctr: 16 ± 5; EGF: 53 ± 3; mPGES-1 knockdown clones, Ctr: 25 ± 4; 
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EGF: 28 ± 7. (B) Western blot analysis for E-cadherin and vimentin expression in A549 wild type 
(WT), non-target shRNA and mPGES-1 knockdown (Kd) cells exposed to EGF (25 ng/ml) for 48 h.  
Figure 5. AG1478 inhibits A431 tumor growth in xenograft nude mice. (A) Athymic mice (8 in 
each group) were inoculated with A431 cells and treated with AG1478 (400 µg/mice) or vehicle 
(Ctr, 0.05% MTC) (*P<0.005, **P<0.01). (B) Western blot analysis of mPGES-1 in xenograft 
tumor tissues (50 µg total proteins/lane). Quantification of mPGES-1 expression in tumors is 
reported as Arbitrary Density Unit (ADU) and represented the ratio between mPGES-1 and Actin 
expression. For each tumor sample analyzed for immune-histochemistry, it is shown their volume 
as mm3. (C) Representative images of histopathological analysis of mPGES-1 (brown) in tumor 
sections from control (top) or AG1478 (bottom) treated mice. Scale bars indicate 100 µm. Images 
taken at 40X. 
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